Lipoprotein (Lp) [a] consists of a low-density lipoprotein (LDL) like moiety bound to a highly glycosylated apolipoprotein (a) particle and an apolipoprotein B-100 particle linked via a single disulfide bond (Figure 1). Since its discovery in 1963 by Kare Berg, Lp(a) has gone relatively unnoticed in cardiovascular (CV) risk reduction algorithms (1). More recently, greater attention has been afforded to Lp(a) with growing evidence suggesting its causality in the development of atherosclerotic cardiovascular disease (ASCVD), culminating in a recent consensus statement published by the ESC (2).
